BACKGROUND AND OBJECTIVES: Chronic inflammation may play a role in chronic kidney disease (CKD) progression. CRP gene polymorphisms are associated with serum C-reactive protein (CRP) concentrations. It is unknown if CRP polymorphisms are associated with CKD progression or modify the effectiveness of anti-hypertensive therapy in delaying CKD progression. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We genotyped 642 participants with CKD from the African American Study of Kidney Disease and Hypertension (AASK), selecting five tag polymorphisms: rs2808630, rs1205, rs3093066, rs1417938, and rs3093058. We compared the minor allele frequencies (MAF) of single nucleotide polymorphisms (SNPs) in AASK to MAFs of African Americans from NHANES III. Among AASK participants, we evaluated the association of SNPs with CRP levels and prospectively with a composite: halving the GFR, ESRD, or death. RESULTS: The MAF was higher for the rs2808630_G allele (P = 0.03) and lower for the rs1205_A allele (P = 0.03) in the AASK compared with NHANES III. Among AASK participants, the rs3093058_T allele predicted higher CRP concentrations (P < 0.0001) but not CKD progression. The rs2808630_GG genotype was associated with higher risk of the composite endpoint compared with the AA genotype (P = 0.002). Participants with the rs2808630_GG genotype on angiotensin converting enzyme inhibitors (ACEIs) versus beta blockers had increased risk of progression (P = 0.03). CONCLUSION: CRP SNPs that were associated with higher levels of CRP did not predict CKD progression. The rs2808630_GG genotype was associated with higher risk of CKD progression, and in patients with this genotype, ACEIs did not slow progression.
BACKGROUND AND OBJECTIVES: Chronic inflammation may play a role in chronic kidney disease (CKD) progression. CRP gene polymorphisms are associated with serum C-reactive protein (CRP) concentrations. It is unknown if CRP polymorphisms are associated with CKD progression or modify the effectiveness of anti-hypertensive therapy in delaying CKD progression. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We genotyped 642 participants with CKD from the African American Study of Kidney Disease and Hypertension (AASK), selecting five tag polymorphisms: rs2808630, rs1205, rs3093066, rs1417938, and rs3093058. We compared the minor allele frequencies (MAF) of single nucleotide polymorphisms (SNPs) in AASK to MAFs of African Americans from NHANES III. Among AASK participants, we evaluated the association of SNPs with CRP levels and prospectively with a composite: halving the GFR, ESRD, or death. RESULTS: The MAF was higher for the rs2808630_G allele (P = 0.03) and lower for the rs1205_A allele (P = 0.03) in the AASK compared with NHANES III. Among AASK participants, the rs3093058_T allele predicted higher CRP concentrations (P < 0.0001) but not CKD progression. The rs2808630_GG genotype was associated with higher risk of the composite endpoint compared with the AA genotype (P = 0.002). Participants with the rs2808630_GG genotype on angiotensin converting enzyme inhibitors (ACEIs) versus beta blockers had increased risk of progression (P = 0.03). CONCLUSION:CRP SNPs that were associated with higher levels of CRP did not predict CKD progression. The rs2808630_GG genotype was associated with higher risk of CKD progression, and in patients with this genotype, ACEIs did not slow progression.
Authors: F Scolari; A Amoroso; S Savoldi; G Mazzola; E Prati; B Valzorio; B F Viola; B Nicola; E Movilli; M Sandrini; M Campanini; R Maiorca Journal: Am J Kidney Dis Date: 1999-05 Impact factor: 8.860
Authors: Chao-Hung Wang; Shu-Hong Li; Richard D Weisel; Paul W M Fedak; Aaron S Dumont; Paul Szmitko; Ren-Ke Li; Donald A G Mickle; Subodh Verma Journal: Circulation Date: 2003-03-17 Impact factor: 29.690
Authors: Vaidyanathapuram S Balakrishnan; Daqing Guo; Madhumathi Rao; Bertrand L Jaber; Hocine Tighiouart; Richard L Freeman; Chao Huang; Andrew J King; Brian J G Pereira Journal: Kidney Int Date: 2004-04 Impact factor: 10.612
Authors: W H Linda Kao; Michael J Klag; Lucy A Meoni; David Reich; Yvette Berthier-Schaad; Man Li; Josef Coresh; Nick Patterson; Arti Tandon; Neil R Powe; Nancy E Fink; John H Sadler; Matthew R Weir; Hanna E Abboud; Sharon G Adler; Jasmin Divers; Sudha K Iyengar; Barry I Freedman; Paul L Kimmel; William C Knowler; Orly F Kohn; Kristopher Kramp; David J Leehey; Susanne B Nicholas; Madeleine V Pahl; Jeffrey R Schelling; John R Sedor; Denyse Thornley-Brown; Cheryl A Winkler; Michael W Smith; Rulan S Parekh Journal: Nat Genet Date: 2008-09-14 Impact factor: 38.330
Authors: B Descamps-Latscha; A Herbelin; A T Nguyen; P Roux-Lombard; J Zingraff; A Moynot; C Verger; D Dahmane; D de Groote; P Jungers Journal: J Immunol Date: 1995-01-15 Impact factor: 5.422
Authors: Vasiliki Michopoulos; Alex O Rothbaum; Tanja Jovanovic; Lynn M Almli; Bekh Bradley; Barbara O Rothbaum; Charles F Gillespie; Kerry J Ressler Journal: Am J Psychiatry Date: 2014-12-12 Impact factor: 18.112
Authors: Adriana M Hung; Christianne L Roumie; Robert A Greevy; Xulei Liu; Carlos G Grijalva; Harvey J Murff; Marie R Griffin Journal: Pharmacoepidemiol Drug Saf Date: 2013-06 Impact factor: 2.890
Authors: M I Danila; A O Westfall; K Raman; L Chen; R J Reynolds; L B Hughes; D K Arnett; G McGwin; A J Szalai; D M van der Heijde; D Conn; L F Callahan; L W Moreland; S L Bridges Journal: Genes Immun Date: 2015-07-30 Impact factor: 2.676
Authors: Adriana M Hung; T Alp Ikizler; Marie R Griffin; Kimberly Glenn; Robert A Greevy; Carlos G Grijalva; Edward D Siew; Dana C Crawford Journal: BMC Med Genet Date: 2011-05-11 Impact factor: 2.103
Authors: Teresa K Chen; Michelle M Estrella; Lawrence J Appel; Josef Coresh; Shengyuan Luo; Jochen Reiser; Wassim Obeid; Chirag R Parikh; Morgan E Grams Journal: Am J Kidney Dis Date: 2021-01-01 Impact factor: 11.072